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One year symptom severity 
and health-related quality of life changes 
among Black African patients undergoing 
uterine fibroid embolisation
Charles Mariara1* , Timona Obura2, Nigel Hacking3 and William Stones4,5,6
Abstract 
Background: The main aim in the treatment of symptomatic fibroids by various modalities including uterine fibroid 
embolisation (UFE) is to alleviate symptoms and ultimately improve the quality of life. The efficacy of this modality 
of treatment in Black African women with significant fibroid burden and large uterine volumes is not clear. The main 
objective of the study was to examine potential changes in symptom severity among Black African patients 1 year fol-
lowing UFE for symptomatic uterine fibroids in a resource-constrained setting, rated using a validated questionnaire 
(UFS-QOL). Secondary outcomes examined were changes in quality of life and potential associations with age, parity, 
uterine volume and fibroid number prior to UFE. Additional interventions after UFE were also recorded.
Methods: A prospective before and after study of Black African patients undergoing UFE was undertaken. Par-
ticipants underwent pelvic MR imaging prior to UFE and completed the UFS-QOL, a validated condition-specific 
questionnaire at baseline and at 1 year. Ninety five participants were recruited and data from 80 completing 1 year of 
follow up were available for analysis of changes in the symptom severity scores.
Results: The mean reduction in symptom severity score was 29.6 [95% CI 23.6 to 35.6, P < 0.001] and the mean 
improvement in HRQOL score was 35.7 [95% CI 28.4 to 42.9, P < 0.001]. A greater number of fibroids identified prior to 
UFE was associated with a more substantial improvement in symptom severity score  (rs = 0.28, n = 80, P = 0.013) and 
participants of higher parity reported a greater improvement in HRQOL score (r = 0.336, P = 0.002). Major and minor 
surgical interventions were needed in 5 (6.3%) and 10 (12.5%) participants respectively.
Conclusions: UFE is associated with clinically useful and statistically significant symptom relief in Black African 
patients. Symptom improvement following UFE is not compromised by a large fibroid burden and the rate of subse-
quent intervention is within an acceptable range. UFE is a safe alternative and efforts are needed to widen access to 
this non-surgical treatment modality.
Keywords: Uterine fibroid embolisation (UFE), Uterine fibroid symptom and quality of life questionnaire (UFS-QOL), 
Health-related quality of life (HRQOL), Symptom severity
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Background
Uterine leiomyomas (fibroids) are the commonest solid 
non-cancerous tumors in women of the reproductive 
age group [1] and more than half are asymptomatic [2]. 
Where symptoms prompt clinical presentation this is 
typically for heavy or prolonged menstrual bleeding, pel-
vic pain and pressure symptoms. Fibroids may also be a 
feature in sub-fertility and miscarriage but the relation-
ship between fibroid disease and sub-fertility may be 
coincidental rather than causal [3]. Racial differences 
as regards incidence and severity of uterine fibroids 
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has been documented with women of African descent 
being noted to be approximately three times more likely 
to have fibroids compared to their Caucasian counter-
parts [4]. Studies have demonstrated that women of 
African descent compared to their Caucasian counter-
parts present at a younger age and have more symptoms. 
Women of African descent have bigger and more numer-
ous fibroids with a faster rate of growth [5]. Age related 
reduction in the rate of fibroid growth is seen in Cauca-
sian women but not in those of African descent [6]. The 
pathophysiological basis for such clinical observations is 
unclear and given the lack of clear biological definitions 
of race or ethnicity they should not be over emphasized, 
especially as there is considerable variation in the clinical 
manifestations of fibroids between individuals as well as 
between groups.
Pharmacological interventions in the treatment of 
symptomatic uterine fibroids usually have short term 
effects, some with significant associated costs and adverse 
effects [7]. The principal surgical modalities include hys-
terectomy and myomectomy. Hysterectomy constitutes a 
‘cure’ but is naturally unacceptable to women who desire 
future childbearing. Myomectomy on the other hand is a 
major surgical procedure associated with morbidity and 
appreciable mortality risk even in well-resourced health 
care settings [8]. These hazards are especially problem-
atic in resource-constrained setting where there may 
be limited access to blood transfusion. Uterine fibroid 
embolisation (UFE) is a radiological intervention that 
has increasingly been used in the treatment of sympto-
matic uterine fibroids by interruption of blood flow in 
the uterine arteries which occludes blood supply to the 
fibroid but not to normal myometrium owing to the pres-
ence of many collaterals [9]. While fibroid embolisation 
has become established as a standard treatment option 
in Western countries, its efficacy and safety together with 
understanding of cost considerations in the African set-
ting, which has a substantial burden of fibroid related dis-
ease is not clear. We aimed to examine potential changes 
in symptom severity among Black African patients 1 year 
following UFE for symptomatic uterine fibroids, rated 
using a validated questionnaire (UFS-QOL). We also 
aimed to examine changes in health-related quality of life 
(HRQOL) and potential associations of changes in symp-
tom severity and health-related quality of life with age, 
parity, uterine volume and fibroid number prior to UFE. 
Additional interventions after UFE were also recorded. 
Here we report outcomes 1 year after UFE.
Methods
This was a prospective observational study over a 
1  year period undertaken at the Aga Khan University 
Hospital Nairobi (AKUH-N) including patients with 
symptomatic uterine fibroids who had opted for uter-
ine fibroid embolisation (UFE). The patients had pre-
sented to the gynaecology clinic with symptomatic 
fibroid disease and had been offered treatment options 
including medical approaches, myomectomy (open 
and laparoscopic), hysterectomy (open and laparo-
scopic), hysteroscopic resection and UFE after appro-
priate counselling.
The primary outcome was change in symptom sever-
ity using the uterine fibroid symptom and health-related 
quality of life questionnaire (UFS-QOL) 1 year after the 
procedure. This questionnaire is available in the Addi-
tional file 1. Secondary outcomes examined were changes 
in HRQOL, and potential associations of changes in 
symptom severity and health-related quality of life with 
age, parity, uterine volume and fibroid number prior to 
UFE. Additional interventions after UFE were recorded 
with readmission considered as a complication of the 
procedure. Subsequent myomectomy and hysterectomy 
were classified as major surgical procedures while hyst-
eroscopy and curettage were classified as minor surgical 
procedures.
Following approval by the Aga Khan University 
Research Ethics Committee, participants were enrolled 
into the study by consecutive selection. Potential partici-
pants of Black African descent scheduled for UFE were 
approached after MR imaging of the pelvis. Exclusions 
were made on the basis of clinical assessment, relevant 
clinical investigations and MRI of the uterus and crite-
ria included difficulty in completing English language 
questionnaires, pathology other than fibroids on MRI, 
previous UFE, pregnancy, active infection and suspicion 
of cancer. Patients with a desire to maintain child bear-
ing potential were only recruited after appropriate coun-
seling owing to the uncertain effects of the procedure 
on ovarian function [10]. Written informed consent was 
obtained and a validated English language questionnaire 
instrument, the UFS-QOL [11] was then completed 
by participants after a brief clinical history. The uterine 
fibroid symptom and quality of life questionnaire (UFS-
QOL) is a disease-specific questionnaire. It assesses 
symptom severity and HRQOL in patients with uter-
ine fibroids and consists of an 8-item symptom severity 
scale and 29 HRQOL items covering six domains: Con-
cern, Activities, Energy/Mood, Control, Self-conscious-
ness, and Sexual Function. All items are scored on a 
5-point Likert scale, ranging from “not at all” to “a very 
great deal” for symptom severity items and “none of the 
time” to “all of the time” for the HRQOL items. Symp-
tom severity and HRQOL subscale scores are summed 
and transformed into a percentage scale. The symptom 
severity scale and HRQOL subscale scores are inversely 
related, with higher symptom severity scores indicating 
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greater symptoms and higher HRQOL subscale scores 
indicating better HRQOL.
All questionnaires bore a unique participant identifi-
cation number and names of study participants did not 
appear on them for purposes of confidentiality. The same 
questionnaire (UFS-QOL) was administered again after 
1  year through email and telephone interviews. Partici-
pants were sent reminders after 11 months of the proce-
dure via text messages, telephone calls and email. Follow 
up for clinical assessment after UFE was undertaken by 
each patient’s responsible clinician separate from con-
tacts for study data collection.
The uterine volume, volume of the dominant fibroid 
and number of fibroids prior to UFE were ascertained 
independently by two radiologists using the pre-UFE pel-
vic MRI examination. Volumes were determined by meas-
uring the maximum extent of the uterus and dominant 
leiomyoma in three planes and multiplying the product 
by 0.5233 (ellipsoid volume formula) [12]. An experienced 
interventional radiologist (NH) carried out embolisa-
tion under conscious sedation using spongostan gelfoam 
(ETHICON) in the hospital’s cardiac catheterization suite 
via a transfemoral approach. Pain relief was undertaken 
using a UFE pain relief protocol previously described [13] 
and participants were discharged from hospital within 
24 h of the procedure and provided with oral pain medi-
cation. Participants did not undergo routine follow up MR 
imaging as previous work in our unit indicated that the 
extent of shrinkage did not correlate directly with symp-
tomatic improvement [12]. We based our sample size cal-
culation on the outcomes from the FIBROID Registry [14] 
in which the mean change in symptom severity score was 
−38.94 (SD ± 24.79), SE 0.52. Given a power of 90% with 
a 5% significance level, and a null hypothesis value of 70% 
of the mean change in symptom severity, the sample size 
was 57 having factored an estimated loss to follow-up of 
20%. Data were analysed using STATA version 12 Special 
Edition and summary statistics tabulated. Statistical sig-
nificance of differences was tested using t tests, Wilcoxon 
rank sum tests and Fisher’s exact tests as appropriate 
taking 5% probability as significant. Age, parity, uterine 
volume, volume of the dominant fibroid and number of 
fibroids prior to UFE were categorized into groups for 
analysis using clinically relevant limits. Potential associa-
tions between age, parity, uterine volume, fibroid num-
ber prior to UFE and the outcome variables of symptom 
score change and HRQOL score change were examined 
using Pearson’s correlation coefficient. Scatter plots with 
superimposed regression lines were used to illustrate the 
underlying relationships. Study participants whose data 
were missing were excluded from the final analysis. How-
ever, baseline characteristics for those lost to follow-up 
were compared to those who completed the study.
Results
One hundred and thirteen patients undergoing uterine 
fibroid embolisation (UFE) during the study period were 
identified as eligible to participate and were approached. 
Of these, eight declined.
Out of the 95 participants who consented to partici-
pate in the study, 15 were lost to follow up while 80 (84%) 
completed follow up and were included in the final anal-
ysis (Fig.  1). All participants were able to communicate 
in the English language. Seventy eight participants com-
pleted their follow up questionnaires online while two 
completed via the telephone. The participants who were 
lost to follow-up were similar to those who completed 
the study in terms of age, parity, uterine volume, vol-
ume of dominant fibroid, number of fibroids before UFE, 
symptom severity scores, and HRQOL scores (Additional 
file  2: Table S1). The characteristics of the participants 
were skewed and were therefore presented as median 
and inter quartile range. The median uterine volume 
(IQR) was 678 ml (486–1121) and the median dominant 
fibroid volume (IQR) was 124 ml (54–272). Regarding the 
location of the dominant fibroid, 78% were intramural/
transmural, 12% submucosal, and 10% subserosal with 
majority of participants having at least one submucosal 
fibroid. Two-thirds of study participants had more than 
ten fibroids (Additional file 2: Table S1).
Primary outcome
The mean change (improvement) in the symptom 
severity score was −29.6 (SD  ±  27.1) [95% CI −35.6 
to −23.6, P < 0.001]. The median symptom score (IQR) 
at 1 year was 15.6 (6.3–35.9). Sixty eight study partici-
pants (85%) recorded an improvement in their symp-
tom severity score. Nine participants (11%) did not 
record an improvement in either their symptom sever-
ity or HRQOL score. Three participants recorded no 
change in symptom score but had very slight improve-
ment in their health-related quality of life. Seven par-
ticipants (9%), all of whom were above the age of 40 
reported amenorrhoea by 1 year. Figure 2 presents the 
distribution of symptom severity scores at baseline and 
at 1 year.
Secondary outcomes
The mean change (improvement) in HRQOL score was 
35.7 (SD ±  32.7) [95% CI 28.4 to 42.9, P  <  0.001], with 
significant improvement in all six domains (Additional 
file  2: Table S2). The median HRQOL score (IQR) at 
1 year was 89.7 (66.4–96.6). Figure 3 presents the distri-
bution of HRQOL scores at baseline and at 1 year. There 
was a strong and significant positive correlation between 
improvements in symptom severity score and HRQOL 
(r = 0.76, P < 0.001).
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There was a modest but significant correlation between 
fibroid number before UFE and change in symptom 
severity score  (rs = 0.28, n = 80, P = 0.013). There was no 
significant correlation between change in symptom sever-
ity score and age (r = 0.110, P = 0.332), parity (r = 0.138, 
P  =  0.222) or uterine volume (r  =  0.114, P  =  0.320). 
There was a modest statistically significant correlation 
between parity and change in the health-related quality of 
life score (r = 0.336, P = 0.002). There was no significant 
correlation between change in the health-related quality 
of life score and age (r = 0.109, P = 0.338), uterine volume 
(r = −0.079, P = 0.492) or fibroid number prior to UFE 
 (rs = 0.16, n = 80, P = 0.166).
During the 1  year follow-up period, 18 (22.5%) study 
participants required subsequent procedure related care. 
Two patients on medical therapy eventually required a 
surgical intervention. The emergency hospitalisation of 
two participants followed their presentation to the hos-
pital with fever. They were evaluated to exclude infection 
and post embolization syndrome was diagnosed. They 
did not require any surgical intervention. Additional 
file 2: Table S3 illustrates the subsequent care needed for 
the study participants.
Discussion
The present study recruited women of Black African 
descent only so as to reflect the large fibroid burden and 
associated potential complications in this population. 
Interestingly, the symptom and HRQOL scores at 1 year 
in the present study were similar to mean scores of nor-
mal subjects reported in the original UFS-QOL validation 
study. There, normal subjects had a mean symptom sever-
ity score of 22.5 (±21.1) and a mean health-related qual-
ity of life score of 86.4 (±17.7) [11]. In comparison to the 
EMMY trial, in which one quarter of the participants were 
Participants who completed the 
study, n=80
Loss to follow-up, n=15
Patients consented to participate 
in the study, n=95
Patients excluded from the study, n=18
• Not eligible, n=5
• Declined to participate, n=8
• Incomplete symptoms or 
HRQOL score, n=5
Patients undergoing UFE
n=113
Fig. 1 Study profile
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Fig. 2 Box and whisker plots of symptom severity scores at baseline 
and at 1 year
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of African descent, participants in our study had twice as 
large a uterus and dominant fibroid prior to treatment, 
with similar outcomes in symptom improvement: 84% of 
participants in the UAE arm of the EMMY trial reported 
satisfaction after 1  year of the procedure [15]. However, 
the FIBROID registry in which 48% of study participants 
were of African descent reported better outcomes than 
seen here, with a mean change in symptom severity score 
and HRQOL of 38.9 (95% CI 37.9 to 40.0) and 39.7 (95% 
CI 38.6 to 40.7) respectively using the UFS-QOL ques-
tionnaire at the 12 month follow-up. Of note, a majority 
of these patients (67.5%) had fewer than five fibroids [14].
We did not observe any association between change 
in symptom severity score and uterine volume, consist-
ent with an earlier report from our group [12]. However, 
an interesting observation is that those with a higher 
number of fibroids prior to UFE have reported a greater 
improvement in symptoms. This could be due to the 
likelihood of the presence of more symptom-produc-
ing submucosal and intramural fibroids in those with a 
higher number of fibroids. Other studies have reported 
conflicting findings in this regard. A prospective study 
conducted to ascertain if the number, size, or location 
of fibroids affects therapeutic efficacy or complications 
of uterine fibroid embolisation concluded that the stated 
parameters did not impact statistically or clinically on the 
success rate and the probability of complications [16]. 
The FIBROID Registry using the UFS-QOL at 3  years 
evaluated 1916 patients and concluded that smaller lei-
omyoma size and submucosal location was associated 
with a greater improvement in symptom severity score 
[17]. In summary, fibroid number before UFE is more 
important than uterine volume in predicting symptom 
outcomes. However, further studies powered to demon-
strate this difference need to be carried out before such 
a conclusive statement can be made. The present study 
demonstrated a significantly greater improvement in the 
HRQOL in parous compared to nulliparous women, as 
also noted in the FIBROID Registry at 1  year follow-up 
[14]. It is possible that asymptomatic fibroid disease in 
nulliparous women could have a differential impact in the 
six domains of the HRQOL namely: Concern, Activities, 
Energy/Mood, Control, Self-consciousness, and Sexual 
Function. Overall, advice to women as to whether UFE 
will improve quality of life needs to reflect individual 
concerns and perceptions about overall health, preserva-
tion of reproductive capacity and fertility as well as the 
resolution of fibroid symptoms.
Eighteen participants (22.5%) required subsequent care. 
This is consistent with other reports in the literature: the 
EMMY trial reported a re-intervention rate (primarily 
hysterectomy) of 23.5% in the first 2  years [15] while the 
REST trial reported a surgical re-intervention rate of 32% 
at 5 years [18]. A retrospective study evaluating long-term 
clinical and MRI follow up of UFE in patients with a large 
fibroid burden reported a re-intervention rate of 25% at a 
mean follow up of 68 months in patients with a large fibroid 
burden [19]. The majority of our study participants had 
a submucous fibroid which often requires hysteroscopy 
to deal with intracavitary myoma debris. This is consist-
ent with our experience that hysteroscopy/dilatation and 
curettage is the commonest additional procedure needed 
for these patients. Interestingly and despite this possibil-
ity, some studies have demonstrated submucosal location 
to be a predictor of a greater benefit with regard to symp-
tom severity [14]. In our clinical practice we have debated 
whether hysteroscopic resection should be routinely 
offered as an adjunct to UFE for those with submucous 
disease but as most do not in fact require intervention it 
would seem reasonable to defer hysteroscopy unless there 
are symptoms suggestive of retained degenerating tissue.
The finding of increased risk of amenorrhoea with 
age following UFE is consistent with other reports and 
may be due to a higher susceptibility of ovarian tissue to 
ischaemic insult as a feature of reproductive ageing [10, 
17, 20]. Therefore, women who wish to maintain fertil-
ity potential should be counselled fully regarding the 
risk of amenorrhoea in the context of their individual 
circumstances.
The introduction of a non-surgical modality for treat-
ing fibroids is very attractive in the African setting where 
the condition is very common and a cause of substan-
tial interference to normal function and quality of life 
through intractable heavy menstrual bleeding leading to 
severe anemia or extreme pressure symptoms. Certain 
components of safe surgery especially access to blood 
transfusion are frequently challenging in the regional 
context. Cost and the infrastructure necessary to under-
take UFE in a systematic way naturally require careful 
consideration. Regarding the latter, there are synergies 
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Fig. 3 Box and whisker plots of health-related quality of life (HRQOL) 
scores at baseline and at 1 year
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with other emerging clinical service developments such 
as cardiac catheterization laboratories and the avail-
ability of this non-surgical modality of fibroid treatment 
should increase as the capacity for interventional cardi-
ology increases. For the procedure itself, the use of the 
spongostan gelfoam (ETHICON) for embolisation rather 
than the more costly embolic beads and deferring routine 
contrast-enhanced MRI pelvis to predict future fibroid 
regrowth has enabled the cost containment while main-
taining efficacy and safety. Overall, the cost of UFE can 
be considered comparable to that of surgery [21] but 
further work is needed in the region to extend interven-
tional radiology training, access to appropriate facilities 
and careful co-ordination of referral and care across spe-
cialists in radiology and gynaecology in order to render 
this valuable modality accessible to those in need.
Conclusions
We conclude that UFE is associated with a clinically use-
ful and statistically significant symptom relief in Black 
African patients. Women considering the procedure can 
be advised that symptom improvement following UFE is 
not compromised by a large fibroid burden and the rate 
of subsequent intervention is within an acceptable range. 
Furthermore, the number of fibroids is potentially more 
significant than the volume of the uterus in predicting 
likely outcomes.
Limitations
First, 16% of study participants did not complete the post-
procedure questionnaire at 12  months. Thus, the results 
would have been biased towards favourable outcomes 
among UFE patients if these study participants were more 
likely to experience unfavourable outcomes. The similar-
ity of baseline characteristics of those completing and not 
completing follow up is however reassuring. Secondly, 
pharmacological interventions were not considered prior 
to administration of the questionnaires either before or 
after UFE. These pharmacological interventions had the 
potential of altering the symptom and HRQOL scores.
Future research
The influence of pre procedure fibroid number on symp-
tom improvement following UFE.
Risk factors for amenorrhoea following UFE.
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